# Clinical Trials Data KRAS - Document 40

# Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01719380

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Metastatic colorectal cancer\n\* Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens\n\* Life expectancy \u2265 3 months\n\* ECOG performance status \u2264 2\n\nExclusion Criteria:\n\n\* Symptomatic or untreated leptomeningeal disease\n\* Symptomatic brain metastasis\n\* Patients with clinically manifested diabetes\n\* Acute or chronic pancreatitis\n\* Clinically significant cardiac disease\n\nOther protocol-defined inclusion/exclusion criteria may apply.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention KRAS mutation status as either an inclusion or exclusion criterion. Therefore, a patient with a KRAS mutation \*could\* be eligible for the trial, provided they meet all other inclusion criteria and do not meet any exclusion criteria. It's important to note that additional, unspecified criteria may apply, which could include KRAS status. A definitive answer would require reviewing the complete protocol.